Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term escalation. Found 11 abstracts

Chen LL, Paskalev K, Xu X, Zhu J, Wang L, Price RA, Hu W, Feigenberg SJ, Horwitz EM, Pollack A, Ma CM. Rectal dose variation during the course of image-guided radiation therapy of prostate cancer. Radiotherapy and Oncology. 2010 May;95(2):198-202.   PMCID: not NIH funded
Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Mar;64(4):1140-50.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. International Journal of Radiation Oncology Biology Physics. 2005 Jun;62(2):397-405.
Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. International Journal of Radiation Oncology Biology Physics. 2005 Feb;61(2):415-9.
Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M, Gore EM, Tepper JE. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: An astro outcomes initiative. International Journal of Radiation Oncology Biology Physics. 2005 May;62(1):3-19.
Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. New paradigm in dose-finding trials: Patient-specific dosing and beyond phase I. Clinical Cancer Research. 2005 Aug;11(15):5342-6.
Wang L, Hoban P, Paskalev K, Yang J, Li JS, Chen LL, Xiong WJ, Ma CC. Dosimetric advantage and clinical implication of a micro-multileaf collimator in the treatment of prostate with intensity-modulated radiotherapy. MEDICAL DOSIMETRY. 2005 Jan;30(2):97-103.
Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics. 2002 Aug;53(5):1097-105.
Fiveash JB, Hanks G, Roach M, Wang SB, Vigneault E, McLaughlin PW, Sandler HM. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi-institutional review. International Journal of Radiation Oncology Biology Physics. 2000 May;47(2):335-42.
Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Schultheiss TE. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer Journal from Scientific American. 1999 May;5(3):152-8.
Horwitz EM, Hanlon AL, Pinover WH, Hanks GE. Is there a role for short-term hormone use in the treatment of nonmetastatic prostate cancer?. Radiation Oncology Investigations. 1999 Jan;7(4):249-59.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term escalation

escalation radiotherapy carcinoma conformal radiotherapy prostate cancer radiation-therapy radical prostatectomy irradiation adenocarcinoma therapy trial prostate neoplasms dose external-beam radiotherapy late rectal toxicity dose-volume histograms optimization dose-response prostate specific antigen androgen pretreatment nomogram three-dimensional conformal therapy radiation treatment Prostate IMRT prostatectomy prostate-specific antigen chemotherapy IMRT neoadjuvant androgen withdrawal disease-free survival definitive radiotherapy psa era Nuclear Medicine & Medical Imaging Radiology target localization systematic review progression randomized trial local tumor-control re-optimization locally advanced-carcinoma gastrointestinal comparing radical modulated radiation-therapy external beam radiotherapy Radiotherapy errors deprivation less-than-or-equal-to-10 mMLC prognosis irinotecan prostatic neoplasms therapy oncology group antigen nadir stage t1-t2 paclitaxel pelvic irradiation Course of treatment randomized-trial localized carcinoma radiation dosimetry cancer genitourinary morbidity dose-escalation three-dimensional conformal radiotherapy beam radiotherapy estramustine biochemical control PSA nadir follow-up radiation dose phase-iii trial hormones three-dimensional radiotherapy experience setup IGRT gy Oncology neoadjuvant hormonal-therapy metastatic breast-cancer failure design suppression goserelin relapse-free survival radiation therapy close escalation adjuvant 3D-CRT clinical-trials toxicity morbidity photons Rectal dose dose- imrt acute toxicity stereotactic radiosurgery rectal toxicity refractory prostate-cancer prediction quality-of-life local-control ablation leaf width
Last updated on Friday, January 03, 2020